New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

21

Putting patients at the heart of cell and gene therapy

Cell and gene therapies (C&GTs) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C&GTs are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).

23

Q&A With Ogilvy Health’s Global CEO Kim Johnson

Med Ad News spoke with Kim Johnson, the new Global CEO of Ogilvy Health, about how she came to the position, her first days on the job, and how she expects the worldwide agency network will expand in the future.

26

U.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivir

The U.S. health regulator expanded the emergency use authorization for Eli Lilly’s baricitinib for Covid-19, saying the arthritis medicine could now be used without taking Gilead’s drug remdesivir along with the product.

27

FDA Approves First-Ever Interchangeable Biosimilar

The U.S. Food and Drug Administration approved Viatris and Biocon Biologics’ Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product, which is indicated to control high blood sugar in adults with Type 2 diabetes as well as adults and pediatric patients with Type 1 diabetes.

28

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced July 29 the company’s BiovitalsHF solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration.